Gelteq Advances Dual-Track Strategy with Veterinary and Human Clinical Trials, Oral Peptide Ambitions
Key Insights
Gelteq has commenced its first veterinary clinical trial for an antiparasitic (search) drug candidate, with FDA application targeted for later in 2026 in a global animal health market exceeding US$78 billion.
The company plans to launch its first human clinical trial next quarter (beginning July 1, 2026), marking a critical step toward an FDA regulatory pathway for its ingestible gel delivery platform.
A preclinical diabetes (search) study is underway, and Gelteq is developing methods to incorporate peptides (search) and biologics into stable oral formulations, targeting the injection-dependent GLP-1 and insulin markets.
MELBOURNE, Australia – Gelteq Limited (search) (NASDAQ: GELS) is making an ambitious push on two fronts: generating near-term commercial revenue from animal health products while simultaneously advancing a pharmaceutical pipeline that could fundamentally change how patients receive complex biologic therapies. The company's June 17, 2026 corporate update detailed a series of milestones spanning veterinary clinical trials, human clinical trial planning, preclinical diabetes (search) research, and oral peptide delivery development.
"Our objective is to establish Gelteq technology as a scalable delivery platform capable of supporting a broad range of active ingredients across pharmaceutical, animal health and consumer health applications while generating near-term revenue from commercial products," said Nathan Givoni, Chief Executive Officer of Gelteq.
Human Clinical Trial Set to Begin Next Quarter
The most significant pharmaceutical milestone is the planned commencement of Gelteq's first human clinical trial, expected to begin next quarter (starting July 1, 2026). The company has completed trial planning and anticipates the study will advance its pharmaceutical program toward a potential FDA regulatory pathway. The human trial is positioned as a critical inflection point, with the potential to generate data supporting continued platform development and informing the company's broader regulatory strategy.
Targeting the Oral Peptide Frontier
In parallel, Gelteq has initiated a preclinical study evaluating a diabetes (search) medication powered by its proprietary gel technology. The study is expected to generate data on formulation performance, dosing, and delivery to inform future clinical development. Diabetes represents one of the largest and fastest-growing chronic-disease categories worldwide, and the company believes a gel-based oral delivery format could offer meaningful advantages in dosing and patient compliance.
More ambitiously, Gelteq is developing methods to incorporate peptides (search) and peptide-based therapeutics into stable oral formulations. This targets compounds traditionally delivered by injection, including the rapidly expanding class of GLP-1 agonists (search) used for diabetes (search) and weight loss, as well as an emerging generation of therapies in development. The company noted that demand for patient-friendly oral alternatives continues to grow, driven by the rapid global uptake of injectable peptide therapeutics and rising interest in novel compounds being developed specifically for oral administration.
Veterinary Program as Proving Ground
Gelteq has commenced its first veterinary clinical trial evaluating an antiparasitic (search) drug candidate, building on the FDA's prior acceptance of the company's suitability petition. The trial is expected to generate data on safety, efficacy, and formulation performance, with a planned FDA application targeted for later in 2026. Clinical trial results are expected in July 2026.
The global animal health market is estimated to exceed US$78 billion in 2026, with antiparasitic (search) treatments representing a significant segment. Gelteq also successfully completed palatability trials in collaboration with Kemin Industries (search), demonstrating strong canine acceptance and confirming the technology's ability to mask bitter functional ingredients without compromising palatability.
Financial Position and Strategic Financing
On May 7, 2026, Gelteq signed a strategic debt financing of up to US$3.5 million with an institutional investor. An initial US$1 million tranche was funded upon closing through a convertible promissory note, with a further US$2.5 million contingent on shareholder approval. A shareholder meeting to vote on the debt financing is scheduled for June 18, 2026. The financing does not require repayments for at least six months from the initial closing, preserving operational flexibility during the next phase of commercialization.
Commercial Validation and Global Expansion
Gelteq successfully manufactured a commercial product for a new customer in the East Asian region, with delivery expected in June 2026. The company views this as validation of its ability to formulate, manufacture, and deliver new commercial products at scale.
Further strengthening its operational footprint, Gelteq established a Center of Excellence in Guangdong Province, China, providing strategic access to one of the world's most active biopharmaceutical markets. Cross-border out-licensing transactions originating from China were estimated at nearly US$60 billion in deal value in the first quarter of 2026 alone, opening potential partnership and licensing pathways across Asia.
"We believe the progress achieved over the past several months highlights the growing breadth of opportunities for Gelteq technology," Givoni added. "From advancing pharmaceutical development programs and expanding our API pipeline, to generating commercial validation and strengthening our operational capabilities, we continue to build the scientific, clinical and commercial foundations necessary to support long-term growth."